Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Archived News

Javelin Pharmaceuticals, Inc. Granted Commercially Important U.S. Patent for Intranasal Ketamine

Thursday, September 27, 2007

Extends Patent Protection for PMI-150 into 2023

Cambridge, MA -- President and founder Fred Mermelstein of Javelin Pharmaceuticals, Inc. (Amex: JAV - News) will discuss, during a presentation at the UBS conference today in New York City, that on September 25, 2007, Javelin was granted a commercially important U.S. patent, enabling greater protection of Javelin’s PMI-150 (intranasal ketamine). U.S. Patent Number 7,273,889, entitled: "NMDA Receptor Antagonist Formulation with Reduced Neurotoxicity," extends protection covering Javelin’s intranasal ketamine drug candidates into 2023.

"This new patent, directed to Javelin’s anticipated commercial formulations, recognizes Javelin’s continuing ability to develop first in class, novel pharmaceutical product formulations to address unmet medical needs in the acute pain care market," said Dr. Mermelstein. "Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain. It will be well-suited for both civilian and military use in medically supervised settings." Dr. Mermelstein added, "Supplemental New Drug Applications are planned for PMI-150 to include use as an adjuvant to opioids and for breakthrough cancer pain. We look forward to our pre-NDA meeting with the FDA, currently scheduled for November and anticipate filing our NDA for PMI-150 in mid-2008, so today’s news is very exciting for the program and shareholders alike."

"We are very excited to have this important pharmaceutical composition patent issue," said David Bernstein, Javelin’s General Counsel and Chief Intellectual Property Counsel. "This patent broadens our overall intellectual property portfolio and adds further strength specifically in ketamine. At the same time, it significantly extends the term of commercial exclusivity for Javelin’s intranasal ketamine products."

About Ketamine

Ketamine, a non-opiate, is an N-methyl-D-aspartate (NMDA) receptor antagonist that has been in clinical use for over 30 years. Since its approval by the FDA, ketamine has been safely used as an anesthetic in tens of thousands of patients. NMDA receptors are located in the central nervous system and play a role in the perception of acute and chronic pain. Ketamine, at lower doses than those approved for anesthetic use, has been reported in the medical literature to be an effective analgesic for post operative settings, nerve injury pain, and pain during medical procedures, such as burn dressing changes.

About PMI-150 (Intranasal Ketamine)

The Company is developing PMI-150, a proprietary nasal formulation of ketamine, for several intended indications. One indication, for which clinical efficacy trials have been completed, is as an emergency analgesic intended for military and civilian use. The Company anticipates undertaking additional clinical studies aimed at broadening PMI-150's potential indications. Javelin believes that PMI-150 is optimized for use as a pain medication and may offer a safe, non-opioid alternative for the treatment of moderate-to-severe pain. Prior randomized, double-blinded, placebo-controlled phase II clinical studies of PMI-150 have demonstrated rapid, statistically significant relief of moderate to severe postoperative and breakthrough pain.

About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in Phase 3 clinical development. One of these Phase 3 drug candidates, Dyloject™, is currently under review for Marketing Authorization Application (MAA) approval in Europe. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at

Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free